A Medical Research Charity, UK

Oxford Oracle reviewed the patent portfolio for the medical research charity, a UK charity that funds the Kennedy Institute of Rheumatology. The trust held over 100 granted patents from world-leading scientists including the team that developed Infliximab, the first anti-TNF therapy. Annual maintenance costs for the portfolio were considerable, as were the skills required to successfully commercialise the assets. The client encountered complex market positioning and operational challenges in commercialising high-potential intellectual property assets while navigating tight regulatory standards and evolving international competition.

The project involved a detailed analysis of each patent family to assess commercial potential. Oxford Oracle deployed a multidisciplinary advisory team to execute comprehensive technical due diligence, design bespoke commercialisation roadmaps, and establish standardized stage-gate evaluation metrics.

Oxford Oracles enabled the medical research charity to rationalise their patent portfolio and conferred a significant cost saving. Furthermore, Oxford Oracle supported the client in the commercialisation of those patent families with the greatest market opportunity through its network of licensees, resulting in the realisation of new licensing income. Updated: Steve Cleverley Aug 2020 Furthermore, the engagement established a permanent, scalable operational blueprint, driving long-term strategic alignment, continuous revenue growth, and enhanced institutional reputation across global innovation networks.